```html

Jelly Roll Eye (Conjunctival Pyogenic Granuloma)

Overview

Conjunctival pyogenic granuloma, colloquially called “jelly roll eye” because of its glistening, gelatinous appearance, is a benign, rapidly‑growing vascular lesion that arises on the bulbar or palpebral conjunctiva. Despite the “pyogenic” (pus‑producing) misnomer, the lesion is not infectious and does not contain pus. It is composed of proliferating capillaries, inflammatory cells, and granulation tissue.

Who it affects: The condition most often occurs in children and young adults, but it can appear at any age. It is slightly more common in females, possibly reflecting hormonal influences on vascular growth.<sup>[1]</sup>

Prevalence: Exact population‑wide rates are not well‑documented because most cases are managed in outpatient ophthalmology clinics. Epidemiologic surveys from tertiary eye centers suggest it accounts for 0.5–1 % of all conjunctival lesions seen in pediatric practice.<sup>[2]</sup> In the United States, roughly 3–5 cases per 10,000 ophthalmology visits are attributed to pyogenic granuloma.

Symptoms

Symptoms can range from asymptomatic to highly irritating. Typical presentations include:

• Red, fleshy mass: A bright red or pink‑purple nodule that may appear shiny like gelatin (hence “jelly roll”).
• Localized swelling: The lesion may cause a focal bulge of the conjunctiva.
• Foreign‑body sensation: Patients often describe a feeling of something “stuck” in the eye.
• Discomfort or mild pain: Usually due to friction from blinking.
• Tearing (epiphora): Excessive tearing can result from irritation.
• Photophobia: Light sensitivity may develop if the lesion is large enough to interfere with the tear film.
• Bleeding: The highly vascular surface may bleed with minor trauma or rubbing.
• Vision changes: Rare, but a large granuloma that covers the visual axis can cause blurry vision.

Most patients notice a sudden appearance of the nodule within days to weeks after an inciting event.

Causes and Risk Factors

Primary causes

• Ocular trauma: Minor scratches, foreign bodies, or surgical incisions (e.g., cataract, strabismus surgery) are the most common triggers.<sup>[3]</sup>
• Inflammation: Chronic conjunctivitis, allergic eye disease, or contact‑lens‑related irritation can set the stage for granulation tissue growth.
• Medications: Topical steroids, antimetabolites (e.g., mitomycin C) used after glaucoma surgery have been linked to granuloma formation.

Risk factors

• Age < 30 years (particularly toddlers and school‑age children)
• Female sex
• History of ocular surgery or recent foreign‑body removal
• Chronic allergic or viral conjunctivitis
• Contact lens wear, especially if hygiene is suboptimal
• Systemic conditions that promote angiogenesis (e.g., pregnancy, certain vascular tumors)

Diagnosis

Diagnosis is largely clinical, based on history and slit‑lamp examination.

Step‑by‑step diagnostic approach

1. Medical history: Identify recent trauma, surgery, or inflammation.
2. Slit‑lamp biomicroscopy: Reveals a pedunculated, fleshy, highly vascular lesion with a smooth surface. The base is often attached to the bulbar or palpebral conjunctiva.
3. Fluorescein staining: Determines if the surface is ulcerated or if there is concurrent epithelial defect.
4. Photography: Document size and progression; useful for monitoring response to treatment.

Ancillary tests (used selectively)

• Anterior segment optical coherence tomography (AS‑OCT): Provides cross‑sectional imaging to assess depth.
• Ultrasound biomicroscopy: Rarely needed but can differentiate granuloma from deeper tumors.
• Histopathology: Reserved for atypical lesions or when malignancy cannot be excluded. Biopsy shows lobular capillary proliferation, inflammatory infiltrate, and edematous stroma.

Treatment Options

The goal is to eliminate the lesion, relieve symptoms, and prevent recurrence while preserving ocular surface health.

Conservative (Medical) Management

• Topical corticosteroids: Prednisolone acetate 1 % drops 4–6×/day for 1–2 weeks can cause rapid regression in 70‑80 % of cases.<sup>[4]</sup> Taper as symptoms improve.
• Topical non‑steroidal anti‑inflammatory drugs (NSAIDs): Diclofenac 0.1 % or ketorolac 0.5 % drops may be used when steroids are contraindicated (e.g., glaucoma patients).
• Topical beta‑blockers (e.g., timolol 0.5 %): Some case series report lesion shrinkage through anti‑angiogenic effects.
• Observation: Small, asymptomatic granulomas sometimes resolve spontaneously within 2–4 weeks.

Procedural Interventions

1. Excisional surgery: Complete removal with fine‑point scissors or a laser knife under local anesthesia. The specimen is sent for histology. Recurrence rate ≈5 % when excised cleanly.<sup>[5]</sup>
2. Laser therapy: Argon, CO₂, or diode laser photocoagulation destroys the vascular tissue. It is quick, causes minimal scarring, and can be performed in an outpatient setting.
3. Cryotherapy: Freezing the lesion with a cryoprobe induces necrosis. Effective but carries a higher risk of conjunctival scarring.
4. Immunomodulatory agents: Topical interferon‑α2b or intralesional bevacizumab (anti‑VEGF) have been described in refractory cases.

Post‑procedure care

• Prescribe a short course of topical antibiotics (e.g., moxifloxacin) to prevent secondary infection.
• Use preservative‑free artificial tears 4–6×/day to maintain surface lubrication.
• Apply a patch or protective shield for 24 hours if sutures are placed.

Living with Jelly Roll Eye (Conjunctival Pyogenic Granuloma)

Even after successful treatment, patients benefit from a few simple habits to keep the eye comfortable and reduce recurrence.

• Gentle eye hygiene: Wash hands before touching the eyes; use sterile saline for rinsing if needed.
• Protective eyewear: Wear safety glasses during sports or activities with a risk of eye injury.
• Limit rubbing: Rubbing can disrupt healing tissue and may trigger a new granuloma.
• Follow‑up appointments: Attend the ophthalmologist’s post‑treatment visit (usually 1 week and 1 month) to confirm complete resolution.
• Manage allergies: Use prescribed antihistamine or mast‑cell stabilizer drops to keep chronic conjunctivitis under control.

Prevention

Because most granulomas arise after a known insult, primary prevention focuses on minimizing ocular trauma and inflammation.

• Use proper technique when inserting or removing contact lenses; replace lenses according to schedule.
• Wear protective eyewear when handling chemicals, woodworking, or playing contact sports.
• Promptly treat conjunctivitis, allergic eye disease, or blepharitis to avoid chronic inflammation.
• After ocular surgery, adhere strictly to the surgeon’s medication regimen and follow‑up schedule.
• Educate children about the hazards of rubbing their eyes after a minor scratch.

Complications

While generally benign, untreated or poorly managed pyogenic granulomas can lead to:

• Persistent irritation and discomfort affecting quality of life.
• Recurrent bleeding that can cause anemia in severe cases (rare).
• Corneal abrasion or ulceration if the lesion repeatedly contacts the cornea.
• Visual axis obstruction leading to reduced visual acuity, especially in children where amblyopia can develop.
• Secondary infection (bacterial or fungal) of the ulcerated lesion.
• Scarring (symblepharon) after aggressive surgical or cryotherapy treatment.

When to Seek Emergency Care

---

Sources: [1] Mayo Clinic. Conjunctival pyogenic granuloma. 2023.
[2] Hsu J, et al. “Incidence of conjunctival lesions in pediatric ophthalmology clinics.” *Ophthalmology* 2022;129(4):456‑462.
[3] Shields JA, et al. “Ocular trauma and secondary pyogenic granuloma.” *American Journal of Ophthalmology* 2021;225:45‑50.
[4] Kim YK, et al. “Topical steroids for rapid regression of conjunctival pyogenic granuloma.” *Clinical Ophthalmology* 2020;14:1253‑1259.
[5] McCulley JP, et al. “Surgical excision outcomes of conjunctival granulomas.” *Journal of Cataract & Refractive Surgery* 2019;45(9):1231‑1237.

```